About: A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report
Creator	Luo, Hong Li, Honghui Sun, Xun Li, Chuang Chen, Yanhui Dai, Yanni Gong, Tiefeng Huang, Xiaoying Long, Haifeng Luo, Baowei Luo, Junbiao Mei, Hua Peng, Hongbing Wang, Weizhong Wang, Xingxing
Source	Medline; PMC; WHO
abstract	Acute respiratory distress syndrome virus-2 (SARS-CoV-2) responsible for coronavirus disease 2019 (COVID-19) infection, which causes global public health emergencies, has sped widely for more than 5 months and has the risk of long-term transmission. No effective treatment has been discovered to date. In the cases we report, the patient continued to deteriorate even after administration of antiviral drugs such as lopinavir/ritonavir, interferon-α, and ribavirin, as well as intravenous injection of meropenem, methylprednisolone, and immunoglobulin. So, we infused the patient with convalescent plasma (CP), and the absolute lymphocyte count increased the next day and returned to normal on the fourth day. Followed by intravenous infusion of mesenchymal stem cells (MSCs), bilateral infiltrates were absorbed and the pulmonary function was significantly improved. We note that the intravenous infusion of CP and MSCs for the treatment of severe COVID-19 patients may have synergistic characteristics in inhibiting cytokine storm, promoting the repair of lung injury, and recovering pulmonary function. We hope to provide a reference for the research direction of COVID-19 clinical strategies.
has issue date	2020-07-16(xsd:dateTime)
bibo:doi	10.1186/s13287-020-01802-8
bibo:pmid	32678017
has license	cc-by
sha1sum (hex)	15ec10209eae1f5820312d74f3b21a4c480fcef3
schema:url	https://doi.org/10.1186/s13287-020-01802-8
resource representing a document's title	A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report
has PubMed Central identifier	PMC7365301
has PubMed identifier	32678017
schema:publication	Stem Cell Res Ther
resource representing a document's body	covid:15ec10209eae1f5820312d74f3b21a4c480fcef3#body_text
is schema:about of	named entity 'risk' named entity 'patients' named entity 'REPORT' named entity 'CONVALESCENT PLASMA' named entity 'MESENCHYMAL STEM CELLS' named entity 'EFFECTIVE' named entity 'HOPE' named entity 'BILATERAL' named entity 'MAY HAVE' named entity 'plasma' named entity 'absolute' named entity 'lopinavir/ritonavir' named entity 'mesenchymal stem cells' named entity 'severe' named entity 'patient' named entity 'day' named entity 'infection' named entity 'intravenous injection' named entity 'ribavirin' named entity 'convalescent plasma' named entity 'synergistic' named entity 'global public health' named entity 'virus' named entity 'MSCs' named entity 'long-term' named entity 'interferon-α' named entity 'antiviral drugs' named entity 'pulmonary function' named entity 'intravenous infusion' named entity 'case report' named entity 'convalescent plasma' named entity 'COVID-19' named entity 'synergistic' named entity 'titer' named entity 'Antiviral therapy' named entity 'pneumonia' named entity 'immunoregulation' named entity 'clinical characteristics' named entity 'synergistic' named entity 'COVID' named entity 'chest CT' named entity 'convalescence' named entity 'cytokine storms' named entity 'immune response' named entity 'virus' named entity 'COVID-19' named entity 'convalescent plasma' named entity 'viral load' named entity 'COVID' named entity 'chest CT' named entity 'multiple organ dysfunction syndrome' named entity 'cytokine storm' named entity 'virus' named entity 'C-reactive protein' named entity 'exudative' named entity 'D-dimer' named entity 'clinical symptoms' named entity '1:160' named entity 'virus' named entity 'SARS' named entity 'dyspnea' named entity 'COVID-19' named entity 'exudative' named entity 'cytokine storms' named entity 'COVID' named entity 'chest CT' named entity 'MSCs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software